title: Literature review of human papillomavirus vaccine acceptability among women over 26 years.
abstract: Vaccines for the human papillomavirus (HPV) are currently licensed for females, ages 9 through 26 years old in the U.S., and for adult women up to 45 years in some countries such as Australia. As licensure for adult women, over 26 years, is sought in other countries, it will be important to determine the acceptability to them. We reviewed the available articles on adult opinions and acceptability of vaccinating women against HPV. Predictors of acceptability included barriers, knowledge, risk, age, and marital status. Overall, acceptability rates were high, if adequate information was given and the cost was affordable.
authors.affiliation: Department of Pediatrics, University of Texas Medical Branch, 301 University Boulevard, Galveston, TX 77555-0319, United States.
authors.forename: Lora L
authors.initials: LL
authors.lastname: Black
authors.forename: Gregory D
authors.initials: GD
authors.lastname: Zimet
authors.forename: Mary B
authors.initials: MB
authors.lastname: Short
authors.forename: Lynne
authors.initials: L
authors.lastname: Sturm
authors.forename: Susan L
authors.initials: SL
authors.lastname: Rosenthal
mesh_terms: D000328:Adult; D003142:Communication; D007722:Health Knowledge, Attitudes, Practice; D006801:Humans; D053918:Papillomavirus Vaccines / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D010342:Patient Acceptance of Health Care; D012306:Risk; D012959:Socioeconomic Factors; D014930:Women
chemical_list: D053918:Papillomavirus Vaccines